Effects of drugs on the fetus

Seminars in Fetal and Neonatal Medicine

Volumn 10, Issue 2, 2005, Pages 139-147

  Jacqz Aigrain, E ^a   Koren, Gideon ^b,c  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Angiotensin receptor antagonist; Fetus; Malformation; Newborn; Pregnancy; Serotonin reuptake inhibitor; Toxicity; Withdrawal

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIVIRUS AGENT; ANTIVITAMIN K; ARAZANAVIR; CANDESARTAN; CARBAMAZEPINE; DIETHYLSTILBESTROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GLUCOCORTICOID; HYDROCHLOROTHIAZIDE; INDOMETACIN; IRBESARTAN; LOPINAVIR; LOSARTAN; METHYLDOPA; NELFINAVIR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTANOID; QUINAPRIL; RETINOIC ACID; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; WARFARIN; ZIDOVUDINE;

ABDUCENS NERVE PARALYSIS; ABORTION; ADENOCARCINOMA; AGENESIS; ANURIA; APLASIA; BEHAVIOR DISORDER; BLINDNESS; BRAIN MALFORMATION; CANCER; CARDIOVASCULAR DISEASE; CEREBRAL PALSY; CLEFT FACE; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CONVULSION; CRYING; CRYPTORCHISM; DANDY WALKER SYNDROME; DEPRESSION; DRUG HALF LIFE; EATING DISORDER; EBSTEIN ANOMALY; ECTOPIC TISSUE; EMBRYOPATHY; EPICANTHUS; EXTERNAL EAR MALFORMATION; FACE DYSMORPHIA; FACIAL NERVE PARALYSIS; FALLOT TETRALOGY; FETAL HEMORRHAGE; FETUS DISEASE; GENITAL MALFORMATION; GESTATION PERIOD; GLIOSIS; HEARING LOSS; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HERNIA; HUMAN; HYDROCEPHALUS; HYPERTELORISM; HYPOPLASIA; HYPOSPADIAS; HYPOTENSION; INTELLECTUAL IMPAIRMENT; INTRAUTERINE GROWTH RETARDATION; IRRITABILITY; KIDNEY DISEASE; KIDNEY FAILURE; LIMB MALFORMATION; LOW BIRTH WEIGHT; LOW SET EAR; MACROCEPHALY; MENTAL DEFICIENCY; MICROCEPHALY; MICROGNATHIA; MICROTIA; MINAMATA DISEASE; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; NAIL HYPOPLASIA; NEURAL TUBE DEFECT; NEUROLOGIC DISEASE; NEWBORN OPHTHALMIA; NONHUMAN; NOSE MALFORMATION; OLIGOHYDRAMNIOS; OPTIC NERVE ATROPHY; OPTIC NERVE DISEASE; PATHOLOGICAL REFLEX; PREGNANCY; PREMATURITY; PRENATAL DRUG EXPOSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA DISEASE; RETROGNATHIA; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKELETON MALFORMATION; SKULL DEFECT; SPEECH DISORDER; SPONTANEOUS ABORTION; STILLBIRTH; STRABISMUS; TERATOGENESIS; TREATMENT CONTRAINDICATION; UROGENITAL TRACT MALFORMATION; VAGINA CARCINOMA; WEBBED NECK;

EID: 13444265985     PISSN: 1744165X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.siny.2004.09.015     Document Type: Review

References (55)

1. HP registered user ICH (International Conference on Harmonisation) of technical requirements for the registration of pharmaceuticals for human use Detection of toxicity to reproduction for medicinal products Fed Reg 59 1994 48746
2. G. Koren, and A. Pastuszak Drugs in pregnancy N Engl J Med 338 1998 1128 1137
3. C. Irl Assessing the safety of drugs in pregnancy. The role of prospective cohort studies Drug Saf 22 2000 169 177
4. R.M. Ward Pharmacological treatment of the fetus. Clinical pharmacokinetic considerations Clin Pharmacokinet 28 1995 343 350
5. N.A. Kulin, A. Pastuszak, S.R. Sage, B. Schick-Boschetto, G. Spivey, and M. Feldkamp Pregnancy outcome after maternal use of the new selective serotonin reuptake inhibitors - a prospective controlled multicenter study JAMA 279 1998 609 610
6. T.H. Shepard, R.L. Brent, J.M. Friedman, K.L. Jones, R.K. Miller, and C.A. Moore Update on the new developments in the study of human teratogens Teratology 161 2002 153 161
7. W.G. McBride Thalidomide and congenital anomalies Lancet 2 1961 1358
8. E.J. Lammer, D.T. Chen, R.M. Hoar, N.D. Agnish, P.J. Benke, and J.T. Braun Retinoic acid embryopathy N Engl J Med 313 1985 837 841
9. F.W. Rosa Retinoid embryopathy in humans G. Koren Retinoids in clinical practice. The risk-benefit ratio 1993 M. Dekker New York/US 77 109
10. W. Holzgreve, J.O. Carey, and D.B. Hall Warfarin induced fetal abnormalities Lancet 2 1976 794
11. A.L. Herbst, H. Ulfelder, and C.D. Poskanzer Adenocarcinoma of the vagina. Association of stillbestrol therapy with tumor appearance in young women N Engl J Med 284 1971 878 881
12. H. Klip, J. Verloop, J.D. van Gool, M.E. Koster, C.W. Burger, F.E. van Leeuwen OMEGA Project Group Hypospadias in sons of women exposed to diethylstilbestrol in utero: a cohort study Lancet 30 359 2002 1102 1107
13. S.A. Friedman Pre-eclampsia: a review of the role of prostaglandines Obstet Gynecol 71 1998 1
14. E. Schiff, E. Peleg, M. Goldenberg, T. Rosenthal, E. Ruppin, and M.B. Tamarkin The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies N Engl J Med 321 1989 351 356
15. K. Higby, and C.R. Suiter A risk-benefit assessment of therapies for premature labour Drug Saf 21 1999 35 56
16. S.T. Vermillion, and C.N. Landen Prostaglandin inhibitors as tocolytic agents Semin Perinatol 25 2001 256 262
17. N.A. Chung, G.Y. Lip, M. Beevers, and D.G. Beevers Angiotensin-II- receptor inhibitors in pregnancy Lancet 357 2001 1620 1621
18. S. Uzan, and M. Beaufils Idiopathic recurrent fetal growth retardation and aspirin-dipiridamol therapy Am J Obstet Gynécol 160 1989 763 764
19. J.N. van den Anker, R.C. Schoemaker, W.C. Hop, B.J. van den Heijden, A. Weber, and P.J. Sauer Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age Clin Pharmacol Ther 58 1995 650 659
20. National Institutes for Health. Safety and toxicity of antiretroviral agents in pregnancy Available from: http:aidsinfi.nih.gov/guidelines/perinatal 2003
21. S. Blanche, M. Tardieu, P. Rustin, A. Slama, B. Barret, and G. Firtion Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues Lancet 354 1999 1084 1089
22. B. Barret, M. Tardieu, P. Rustin, C. Lacroix, B. Chabrol, and I. Desguerre Persistent mitochondrial dysfunction in HIV-1 exposed but uninfected patients: clinical screening in a large prospective cohort AIDS 17 2003 1769 1785
23. J.M. Mastrobattista Angiotensin converting enzyme inhibitors in pregnancy Semin Perinatol 21 1997 124 134
24. M. Barr Jr. Teratogen update: angiotensin-converting enzyme inhibitors Teratology 50 1994 399 409
25. M. Hanssens, M.J.N.C. Keirse, F. Vankelecom, and F. Van Assche Fetal and neonatal effects of treatment with angiotensin converting enzyme inhibitors during pregnancy Obstet Gynecol 78 1991 128 135
26. S.G. Spence, H.L. Allen, M.A. Cujierski, J.M. Manson, R.T. Robertson, and R.S. Eydelloth Defining the susceptible period of developmental toxicity for AT1 selective angiotensin II receptor antagonist losartan in rats Teratology 51 1995 367a 382a
27. W.B. Kramer, I.B. Van den Veyver, and B. Kirshon Treatment of polyhydramnios with indomethacin Clin Perinatol 21 1994 615 630
28. J. Martinovic, A. Benachi, N. Laurent, F. Daikha-Dahmane, and M.C. Gubler Fetal toxic effects and angiotensin-II-receptor antagonists Lancet 358 2001 241 242
29. Serreau R, Liutkus A, Luton D, et al. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. Br J Obstet Gynecol, in press.
30. R.L. Brent, and D.A. Beckman Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties: information for clinical teratology counsellors Teratology 43 1991 543 546
31. J.R. Voland, E.P. Hawkins, T.R. Wells, B. Saunders, M. Jones, and K. Benischke Congenital hypernephrotic nephromegaly with tubular dysgenesis: a distinctive inherited renal anomaly Pediatr Pathol 4 1985 231 245
32. J. Bernstein, and L. Barajas Renal tubular dygenesis: evidence of abnormality in the renin angiotensin system J Am Soc Nephrol 5 1994 224 227
33. D.J. Goldstein Effects of third trimester fluoxetine exposure on the newborn Obstet Gynecol 89 1997 7132 7718
34. C. McGrath, A. Buist, and T.R. Norman Treatment of anxiety during pregnancy. Effect of psychotropic drug treatment on the developing fetus Drug Saf 20 1999 171 186
35. T. Vitalis, and J.G. Parnavelos The role of serotonin in early cortical development Dev Neurosci 25 2003 245
36. C.V. Vorhes, K.D. Acuff-Smith, M.A. Schilling, J.E. Fisher, M.S. Moran, and J. Sam A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats Fundam Appl Toxicol 23 1994 194 205
37. V. Hendrick, L.M. Smith, R. Suri, S. Hwang, D. Haynes, and L. Altshuler Birth outcomes after prenatal exposue to antidepressants medication Am J Obstet Gynecol 188 2003 812 815
38. K. Laine, T. Heikkinen, U. Ekblad, and P. Kero Effects of exposure to SSRIs during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations Arch Gen Psychiatry 60 2003 720 726
39. C.D. Chambers, K.A. Johnson, L.M. Dick, R.J. Felix, and K. Lyons John Birth outcomes in pregnant women taking fluoxetine New Engl J Med 335 1996 1010
40. C.A. Chiriboga, M. Vibbert, R. Malof, M.S. Suarez, M.S. Abrams, and M.C. Heagarty Neurological correlation of fetal cocaine exposure: transient hypertonia of infancy and early childhood Pediatrics 96 1995 1070 1077
41. V. Delaney-Black, C. Covington, and J.R. Ostrea Prenatal cocaine and neonatal withdrawal syndrome: evaluation of dose-response relationship Pediatrics 98 1996 735
42. S.N. Mattson, E.P. Riley, L. Gramling, D.C. Delis, and K.L. Jones Heavy prenatal alcohol exposure with or without physical features of fetal alcohol syndrome leads to IQ deficits J Pediatr 131 1997 718
43. A.P. Streissguth, H.M. Barr, P.D. Sampson, and F.L. Bookstein Prenatal alcohol and offspring development in the progeny of mothers who used alcohol during pregnancy Early Human Dev 48 1997 153
44. T.J. Malpas, Ba. Barlow, R Lennox, and L.J. Horwood Maternal methadone dosage and neonatal withdrawal Aust NZ Obstet Gynaecol 35 1995 175 177
45. S. Cnattingius, L.B. Signorello, G. Anneren, B. Clausson, A. Ekbom, and E. Ljunger Caffeine intake and the risk of first-trimester spontaneous abortion N Engl J Med 343 2000 1839 1845
46. D.C. Van Dyke, V.L. Ellingrod, M.J. Berg, J.R. Niebyl, A.L. Sherbondy, and D.G. Trembath Pharmacogenetic screening for susceptibility to fetal malformations in women Ann Pharmacother 34 2000 639 645
47. C.B. Tempfer, C. Schneeberger, and J.C. Huber Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology Pharmacogenomics 5 2004 57 65
48. S. Matalon, S. Schechtman, G. Goldzweig, and Ornoy The teratogenic effect of carbamazepine: a meta-analysis in 1255 exposures Reprod Toxicol 16 2003 9 17
49. B. Kirshon, N. Wasserstrum, R. Willis, G.E. Herman, and E.R. McCabe Teratogenic effects of first trimester cyclophosphamide therapy Obstet Gynecol 72 1988 462 464
50. G.J. Myers, and P.W. Davidson Prenatal methylmercury exposure and children: neurologic, developmental, and behavioral research Environ Health Perspect 106 1998 841 847
51. A.B. Goldberg, M.B. Greenberg, and P.D. Darney Misoprostol and pregnancy N Engl J Med 344 2001 38 47
52. J.W. Hanson, and D.W. Smith The fetal hydantoin syndrome J Pediatr 87 1975 286 290
53. E. Robert, and P. Guimbaud Maternal valproic acid and congenital neural tube defect Lancet 2 1982 937
54. R.E. Dahl, M.S. Scher, D.E. Williamson, N. Robles, and N. Day A longitudinal study of prenatal marijuana use Arch Ped Adol Med 149 1995 143 150
55. J.R. Woods Adverse consequences of prenatal illicit drug exposure Curr Opin Obstet Gynecol 8 1996 403 411